How many institutions own IRD stock?

A company's 13F filings with the Securities and Exchange Commission (SEC) provides investors with comprehensive information about institutional ownership in a listed company, a sign of strength in terms of how many institutions have confidence in that company. The number of institutional investors who currently own IRD shares is 92, representing 55.69% of the company's common stock.

Who are the major shareholders selling Opus Genetics, Inc. stock?

N/A, in the last quarter, reduced its stake in IRD by N/A restricting it's holding to - shares of worth nearly -. N/A also lessened N/A of the IRD shares from its portfolio, reducing its holding to - shares of worth -. N/A also shunned IRD shares holding by N/A last quarter which brought its holding to - shares worth -.

Investors who are buying IRD stock?

As per its latest 13F filing, N/A increased its stake in IRD by N/A in the last quarter. The institutional holder raised its holding to - shares having worth more than -. N/A also added N/A more shares of IRD to its portfolio, raising its holding to - shares of worth -. N/A also increased its IRD shares holding by N/A which brought its holding to - shares worth -.

IRD's major insiders: who are they?

The insider with the most stakes in IRD is Foundation Fighting Blindness Retinal Degeneration Fund , See Remarks at the company. Additionally, IRD stock is highly held by Chief Executive Officer Magrath George and President YERXA BENJAMIN R among others.

Did an insider recently sell IRD stock?

Company executives, directors, and other insiders own 11.04% percent of Opus Genetics, Inc.'s stock. Within the last six months, there have been 15 transaction(s) in which IRD insiders have sold stock, totaling 1.8M shares. Insiders that have sold shares include GAGNON ROBERT E., MAGRATH GEORGE, and SCHACHLE JOSEPH K.

Which insider recently purchased IRD stock?

There have been 0 transaction(s) during the past 6-months in which Opus Genetics, Inc. insiders have bought stock, totalling 0 shares

How much of IRD does insiders own?

Around 13.9M Opus Genetics, Inc. shares are held by insiders, which represents about 11.04% of IRD stock.

Who is the insider with the largest stake?

IRD See Remarks, Foundation Fighting Blindness Retinal Degeneration Fund holds the largest portfolio of the company's shares. IRD shares owned by Foundation total nearly 3.79 million.

Which institution holds the most shares in IRD?

N/A is the largest institutional owner in IRD which holds - shares worth - or N/A of the total IRD shares outstanding followed by N/A with ownership of - shares representing N/A of the IRD ownership. N/A is the third largest stakeholder with - shares or N/A of the ownership worth more than -.

Is Opus Genetics, Inc. stock optionable?

Stock options give the owner the ability but not the obligation to buy or sell a security at a predetermined price and date. Stock options can be classified into two types: puts and calls. A put is a bet on falling stock, and a call is a bet on rising stock. As far as the IRD is concerned, it is a stock which is optionable.

Is there a short position on IRD's shares?

Number of IRD shares short is 10.27M. Shares short is a market sentiment in which investors have sold their shares short in a given stock but have not yet covered them or closed them out.

About how many outstanding IRD shares are there?

As of today, 82.57M shares of IRD are outstanding.

Is there many float in IRD stock?

Float represents the number of tradeable shares in a specific stock. By subtracting restricted and closely-held shares from a firm's total outstanding shares, we can calculate its floating stock. The term "closely-held shares" refers to shares held by employees, major shareholders, and company insiders. At present, IRD has 63.68M shares in float.

IRD short ratio: what is it?

Short ratio is calculated by dividing the number of short shares, short interest or bets that shareholders will sell short from the average daily volume. A higher ratio indicates longer times needed to repurchase borrowed shares (sold). The short ratio for IRD is 8.67.

Stock Ideas

IRD Stock Ownership Breakdown

NASDAQ : IRD

Opus Genetics

$3.35

0.27+8.77%

At Close 4:00 PM

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Stock Outstanding Shares

Making an investment decision in the stock market involves a certain amount of risk, so it's important to thoroughly review a company's stock before making any decisions. Stock float, number of short positions and outstanding shares are among the many factors an investor should take into account.

ShortableYes

OptionableYes

Short Percent Of Outstanding Shares12.43

Short Percent Of Float13.08

Shares Outstanding82.57M

Shares Float63.68M

Shares Short10.27M

Short Ratio8.67

13.08%

Short % of Float

12.43%

Short % of Shares Outstanding

Market Insider

Investors cannot turn a blind eye to insiders as well as institutional ownership. They need to follow insider trades to determine the direction the stock is likely to take.

Major Holders Summary

11.04% Percentage of Shares held by All Insiders

55.69% Percentage of Shares held by All Institutions

62.6% Percentage of Float held by Institutions

Number of Institutions Holding Shares

Institutional Ownership

Date	Holder	% Stake	Shares Held	Total Value ($)	Shares	% Change in Portfolio
No Data

Insiders

Among the IRD insiders holding of 11.04% of the stake in company, FOUNDATION FIGHTING BLINDNESS RETINAL DEGENERATION FUND, See Remarks, holds the largest shares of 3.79M. MAGRATH GEORGE, Chief Executive Officer, is the second largest IRD insider with ownership of 1.73M shares. YERXA BENJAMIN R, President, stands third with possession of 704.11K shares of that stake.

Insiders	Designation	Shares Held
FOUNDATION FIGHTING BLINDNESS RETINAL DEGENERATION FUND	See Remarks	3.79M
MAGRATH GEORGE	Chief Executive Officer	1.73M
YERXA BENJAMIN R	President	704.11K
GAGNON ROBERT E.	Chief Financial Officer	584.38K
JAYAGOPAL ASHWATH	Chief Scientific & Dev. Ofc.	509.23K
SCHACHLE JOSEPH K	Chief Operating Officer	291.44K
ZAREMBA RABOURN AMY	Head of Fin. Quality Assurance	188.67K
GALLAGHER CAM	director	83K

Buying/Selling by Insiders

Date	Insider	Type	Cost	Shares	Value ($)	Shares Total
Jul 23, 2026	GAGNON ROBERT E.	SALE	2.95	7.78K	22.94K	584.38K
Jul 23, 2026	MAGRATH GEORGE	SALE	2.95	9.48K	27.93K	1.73M
Jul 23, 2026	SCHACHLE JOSEPH K	SALE	2.94	4.64K	13.65K	291.44K
Jul 23, 2026	YERXA BENJAMIN R	SALE	2.97	7.43K	22.06K	704.11K
May 18, 2026	FOUNDATION FIGHTING BLINDNESS RETINAL DEGENERATION FUND	SALE	4.35	1.7M	7.4M	3.79M
Apr 23, 2026	SCHACHLE JOSEPH K	SALE	5.22	4.7K	24.52K	296.08K
Apr 23, 2026	YERXA BENJAMIN R	SALE	5.24	7.47K	39.12K	711.54K
Apr 23, 2026	ZAREMBA RABOURN AMY	SALE	5.20	1.64K	8.54K	188.67K
Apr 23, 2026	MAGRATH GEORGE	SALE	5.22	9.51K	49.65K	1.74M
Apr 23, 2026	JAYAGOPAL ASHWATH	SALE	5.19	7.54K	39.16K	509.23K
Apr 23, 2026	GAGNON ROBERT E.	SALE	5.18	7.84K	40.66K	592.16K
Mar 16, 2026	MAGRATH GEORGE	SALE	5.21	24.44K	127.33K	1.75M
Mar 16, 2026	SCHACHLE JOSEPH K	SALE	5.25	3.72K	19.53K	300.78K
Mar 16, 2026	JAYAGOPAL ASHWATH	SALE	5.12	3.72K	19.05K	516.78K
Mar 16, 2026	ZAREMBA RABOURN AMY	SALE	5.25	2.82K	14.77K	190.31K
Dec 29, 2025	GALLAGHER CAM	PURCHASE	1.97	83K	163.42K	83K
Dec 09, 2025	FOUNDATION FIGHTING BLINDNESS RETINAL DEGENERATION FUND	SALE	2.15	4M	8.6M	5.49M
Dec 26, 2024	MAGRATH GEORGE	PURCHASE	0.98	100K	97.6K	599.15K
Nov 21, 2024	YERXA BENJAMIN R	PURCHASE	0.98	10K	9.83K	342.8K
Nov 18, 2024	MAGRATH GEORGE	PURCHASE	1.02	9.71K	9.94K	492.95K
Nov 15, 2024	MAGRATH GEORGE	PURCHASE	1.01	90.29K	91.21K	483.24K

Insider Transaction Summary (6 Months)

SHARESTRANS

PURCHASE00

SALES1.8M15

NET SHARES-1.8M15

SHARES HELD13.9M15

% NET SHARES-112.97%0%

Frequently Asked Questions

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.